News and Events
The results of Phase 2 clinical trials for glaucoma drug QLS-101 have demonstrated a favorable safety and tolerability profile, according to a news release by Qlaris Bio, which licensed the drug in 2019. A positive efficacy signal was also reported. Read the full story on the University of Minnesota College of Pharmacy website.Read more...
The Institute for Therapeutics Discovery and Development (ITDD) has been awarded a new NIH contract entitled "Support for NCATS Medicinal Chemistry for Lead Optimization". The objective of this contract is to support the NIH National Center for Advanced Translational Sciences (NCATS) drug development programs by identifying preclinical drug candidates with improved efficacy, optimized ADME properties, and minimal predicted toxicity. The potential value of this five-year contract is $17,887,012. The program is led by Dr. Vadim J.
Gunda Georg, PhD, has been appointed a Regents Professor of the University of Minnesota. The Regents Professorship is the highest honor the University bestows on its faculty. It recognizes faculty who have made exceptional contributions to the University through teaching, research, scholarship, or creative work, and contributions to the public good.
Gunda Georg was featured in several stories on her work to develop a male birth control pill
Gunda Georg was featured in a KARE-11 story and in
Gunda Georg and Shameem Syeda were featured on the front page of the Star
Rebecca Cuellar and Gunda Georg are featured in the MN Daily story, "Heart-stopping poison could be a promising male birth control, UMN study shows." Georg is also featured in The Student Newspaper story, "Will male contraception be derived from Cupid's arrow?" and The Futurist story, "The Future ofRead more...